Replies to post #48025 on Biotech Values

[poorgradstudent]

This is a pretty serious matter imo.

Previously, there were no rigorous examinations of sequential doxil / hycamtin in platinum refractory patients. That the sequential regimen does so well is surprising because it handily beat out the median survival seen in patients with one less line of therapy (!).

This meant that the company had robust data in hand that demonstrated the utility of the sequential regimen *and* had data in hand suggesting that their experimental drug underperforms a treatment that is readily available.

In effect, they screwed ovarian cancer patients pretty hard by hiding behind the ASCO embargo BS. What telk management did is plainly unethical, and if I was a doc, I'd refuse to work with the company in any manner whatsoever. A small part of the blame (5%) lies at ASCO's doorstep for giving companies this shield, which also ends up depriving patients of critical info regarding available treatments.

[exwannabe]

Telcyta, the new placebo!

Woudn't all the dndn tin foil hats jump on that :-)